Subgroup analysis | Description | Mortality | Requirement for RRT | ||
---|---|---|---|---|---|
Fixed effect model | Random effect model | Fixed effect model | Random effect model | ||
By intervention | Prevention | ORâ=â0.852 (95% CI 0.303â2.395), pâ=â0.7 | ORâ=â0.780 (95% CI 0.235â2.590), pâ=â0.7 | ORâ=â0.584 (95% CI 0.210â1.625), pâ=â0.3 | ORâ=â0.678 (95% CI 0.133â3.450), pâ=â0.6 |
Treatment | ORâ=â1.063 (95% CI 0.832â1.359), pâ=â0.6 | ORâ=â1.065 (95% CI 0.831â1.364), pâ=â0.6 | ORâ=â0.904 (95% CI 0.625â1.413), pâ=â0.8 | ORâ=â1.037 (95% CI 0.568â1.894), pâ=â0.9 | |
By AKI aetiology | Cardio-renal syndrome | ORâ=â1.108 (95% CI 0.734â1.674), pâ=â0.6 | ORâ=â1.114 (95% CI 0.733â1.692), pâ=â0.6 | â | â |
CIN | ORâ=â0.381 (95% CI 0.07â1.996), pâ=â0.2 | ORâ=â0.385 (95% CI 0.07â2.031), pâ=â0.3 | ORâ=â0.211 (95% CI 0.04â0.99), pâ=â0.049 | ORâ=â0.218 (95% CI 0.05â1.04), pâ=â0.055 | |
Post-CPB | ORâ=â1.688 (95% CI 0.388â7.345), pâ=â0.5 | ORâ=â1.5115 (95% CI 0.178â12.869), pâ=â0.7 | ORâ=â4.147 (95% CI 0.449â38.27), pâ=â0.2 | ORâ=â4.075 (95% CI 0.437â38.02), pâ=â0.2 | |
Critical illness (ICU patients) | ORâ=â1.039 (95% CI 0.765â1.411), pâ=â0.8 | ORâ=â1.039 (95% CI 0.764â1.413), pâ=â0.8 | ORâ=â0.940 (95% CI 0.625â1.413), pâ=â0.8 | ORâ=â1.037 (95% CI 0.568â1.894), pâ=â0.9 | |
By control arm treatment | RRT | ORâ=â1.169 (95% CI 0.778â1.757), pâ=â0.4 | ORâ=â1.169 (95% CI 0.775â1.766), pâ=â0.4 | â | â |
Saline/placebo/standard of care | ORâ=â0.618 (95% CI 0.304â1.256), pâ=â0.2 | ORâ=â0.626 (95% CI 0.197â1.994), pâ=â0.4 | ORâ=â1.397 (95% CI 0.736â2.652), pâ=â0.3 | ORâ=â1.393 (95% CI 0.711â2.730), pâ=â0.3 | |
By daily furosemide dose | <â160Â mg | ORâ=â0.931 (95% CI 0.651â1.329), pâ=â0.7 | ORâ=â0.923 (95% CI 0.642â1.326), pâ=â0.7 | ORâ=â0.727 (95% CI 0.466â1.134), pâ=â0.2 | ORâ=â0.703 (95% CI 0.315â1.568), pâ=â0.4 |
â„â160Â mg | ORâ=â1.194 (95% 0.848â1.680), pâ=â0.3 | ORâ=â1.201 (95% CI 0.850â1.695), pâ=â0.3 | â | â |